Abstract
Activating mutations in KRAS are the most common driver mutations in metastatic non-small cell lung cancer (mNSCLC). KRAS-mutant NSCLCs are heterogeneous in their biology and the response of the various KRAS alleles to immune checkpoint inhibitors (ICI) remains unclear. We sought to investigate differential outcomes to ICI among KRAS subtypes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
